📊 LSTA Key Takeaways
Is Lisata Therapeutics, Inc.. (LSTA) a Good Investment?
LSTA is a pre-revenue pharmaceutical company with zero revenue (-83% YoY) and negative operating cash flow of -3.1M annually, indicating ongoing losses with no clear path to commercialization. While the company maintains a strong cash position of $13.1M with minimal debt, this only provides approximately 4+ years of runway at current burn rates—insufficient runway for uncertain drug development success.
Fundamentals show immaterial and declining revenue, extreme negative margins, and heavy operating cash burn. While liquidity is solid near term with no debt and ~12 months of cash, the business lacks visible path to scale or profitability. Without clear, recurring non-dilutive revenue or sharply lower operating losses, dilution and going‑concern risks dominate.
Lisata Therapeutics, Inc.. Key Strengths (LSTA)
- Strong cash position of $13.1M representing 92% of total assets
- Zero long-term debt reduces financial leverage risk
- Solid liquidity ratios (4.23x current, 3.58x quick) indicating no immediate solvency crisis
- Strong liquidity (current ratio 5.76x) with $15.96M cash
- Debt-free balance sheet and low liabilities
- Minimal capex needs and modest EPS YoY improvement
LSTA Stock Risks: Lisata Therapeutics, Inc.. Investment Risks
- Zero revenue with -83% YoY decline suggests loss of commercial operations or failed product pipeline
- Negative operating cash flow of -3.1M annually creates unsustainable burn rate
- Pre-revenue biotech model with unclear timeline to profitability or product commercialization
- Operating losses of -4.9M and net losses of -4.5M with no revenue offset
- Limited cash runway of 4+ years at current burn rate—high execution risk required
- High cash burn (~$16M OCF) implying ~1-year runway
- Severely negative margins and -83% YoY revenue decline
- Elevated dilution/going-concern risk absent funding or cost reduction
Key Metrics to Watch
- Revenue generation timeline and clinical trial progress on pipeline assets
- Operating cash flow trends and ability to reduce burn rate
- Cash balance depletion rate and runway extension through financing or partnerships
- Any announcements of product approvals, partnerships, or successful clinical milestones
- Quarterly operating cash burn and cash runway
- Recurring non-dilutive revenue growth and operating expense trend
Lisata Therapeutics, Inc.. (LSTA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.23x current ratio provides a solid financial cushion.
LSTA Profit Margin, ROE & Profitability Analysis
LSTA vs Healthcare Sector: How Lisata Therapeutics, Inc.. Compares
How Lisata Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lisata Therapeutics, Inc.. Stock Overvalued? LSTA Valuation Analysis 2026
Based on fundamental analysis, Lisata Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lisata Therapeutics, Inc.. Balance Sheet: LSTA Debt, Cash & Liquidity
LSTA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lisata Therapeutics, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.58 indicates the company is currently unprofitable.
LSTA Revenue Growth, EPS Growth & YoY Performance
LSTA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$4.5M | $-0.50 |
| Q3 2025 | N/A | -$4.2M | $-0.49 |
| Q2 2025 | N/A | -$4.7M | $-0.54 |
| Q1 2025 | N/A | -$4.7M | $-0.55 |
| Q3 2024 | N/A | -$4.9M | $-0.59 |
| Q2 2024 | N/A | -$4.0M | $-0.50 |
| Q1 2024 | N/A | -$5.4M | $-0.65 |
| Q3 2023 | N/A | -$5.3M | $-0.65 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lisata Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
LSTA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lisata Therapeutics, Inc.. (CIK: 0000320017)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LSTA
What is the AI rating for LSTA?
Lisata Therapeutics, Inc.. (LSTA) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 83% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LSTA's key strengths?
Claude: Strong cash position of $13.1M representing 92% of total assets. Zero long-term debt reduces financial leverage risk. ChatGPT: Strong liquidity (current ratio 5.76x) with $15.96M cash. Debt-free balance sheet and low liabilities.
What are the risks of investing in LSTA?
Claude: Zero revenue with -83% YoY decline suggests loss of commercial operations or failed product pipeline. Negative operating cash flow of -3.1M annually creates unsustainable burn rate. ChatGPT: High cash burn (~$16M OCF) implying ~1-year runway. Severely negative margins and -83% YoY revenue decline.
What is LSTA's revenue and growth?
Lisata Therapeutics, Inc.. reported revenue of $0.0.
Does LSTA pay dividends?
Lisata Therapeutics, Inc.. does not currently pay dividends.
Where can I find LSTA SEC filings?
Official SEC filings for Lisata Therapeutics, Inc.. (CIK: 0000320017) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LSTA's EPS?
Lisata Therapeutics, Inc.. has a diluted EPS of $-0.50.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is LSTA's fundamental grade?
Based on our AI fundamental analysis in May 2026, Lisata Therapeutics, Inc.. has a D grade with 83% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is LSTA stock overvalued or undervalued?
Valuation metrics for LSTA: ROE of -41.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is LSTA's AI grade for 2026?
Our dual AI analysis gives Lisata Therapeutics, Inc.. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LSTA's free cash flow?
Lisata Therapeutics, Inc..'s operating cash flow is $-3.1M, with capital expenditures of $0.0.
How does LSTA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -41.1% (avg: 15%), current ratio 4.23 (avg: 2).